FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 356:6-9 January 4, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schade, R. Related Article by Zanettini, R. PubMed Citation

In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.¹ The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.¹

This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . . [Full Text of this Article]

Source Information

Dr. Roth is a professor in the Departments of Pharmacology and Medicinal Chemistry, Schools of Medicine and Pharmacy, and director of the National Institute of Mental Health Psychoactive Drug Screening Program at the University of North Carolina, Chapel Hill.

Related Letters:

Dopamine Agonists and Valvular Heart Disease
Stephens J. W., Price D. E., Ionescu A., Linkova H., Ruzicka E., Penicka M., Kast R. E., Altschuler E. L., Ziegler J. L., Bukhman G. Y., Sartiani L., Cerbai E., Mugelli A., Schade R., Andersohn F., Garbe E., Zanettini R., Pezzoli G., Roth B. L.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:1676-1680, Apr 19, 2007. Correspondence

This article has been cited by other articles:

• Huang, X.-P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., Revankar, C., Robers, M., Doucette, C., Roth, B. L. (2009). Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment. Mol. Pharmacol. 76: 710-722 [Abstract] [Full Text]  
• Pena-Silva, R. A., Miller, J. D., Chu, Y., Heistad, D. D. (2009). Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am. J. Physiol. Heart Circ. Physiol. 297: H1354-H1360 [Abstract] [Full Text]  
• Connolly, J. M., Bakay, M. A., Fulmer, J. T., Gorman, R. C., Gorman, J. H. III, Oyama, M. A., Levy, R. J. (2009). Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin. Am. J. Pathol. 175: 988-997 [Abstract] [Full Text]  
• Droogmans, S., Kerkhove, D., Cosyns, B., Van Camp, G. (2009). Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 10: 467-476 [Abstract] [Full Text]  
• Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M., Franken, P. R., Lahoutte, T., Schoors, D., Van Camp, G. (2009). Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am. J. Physiol. Heart Circ. Physiol. 296: H1940-H1948 [Abstract] [Full Text]  
• Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]  
• Delgrange, E., Daems, T., Verhelst, J., Abs, R., Maiter, D. (2009). Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160: 747-752 [Abstract] [Full Text]  
• Sherlock, M., Toogood, A. A, Steeds, R. (2009). Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart 95: 522-523 [Full Text]  
• Elangbam, C. S. (2009). REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. Vet Pathol 46: 10-24 [Abstract] [Full Text]  
• Pei, Y., Rogan, S. C., Yan, F., Roth, B. L. (2008). Engineered GPCRs as Tools to Modulate Signal Transduction. Physiology 23: 313-321 [Abstract] [Full Text]  
• Molitch, M. E. (2008). The Cabergoline-Resistant Prolactinoma Patient: New Challenges. J. Clin. Endocrinol. Metab. 93: 4643-4645 [Full Text]  
• Droogmans, S., Cosyns, B., Van Camp, G. (2008). Pergolide and valvular heart disease: the lower the better?. Eur J Echocardiogr 9: 717-718 [Full Text]  
• Schoen, F. J. (2008). Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering. Circulation 118: 1864-1880 [Abstract] [Full Text]  
• Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T., Snyderwine, E. (2008). Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors. JNCI J Natl Cancer Inst 100: 1282-1289 [Abstract] [Full Text]  
• Lancellotti, P., Livadariu, E., Markov, M., Daly, A. F, Burlacu, M.-C., Betea, D., Pierard, L., Beckers, A. (2008). Cabergoline and the risk of valvular lesions in endocrine disease.. Eur J Endocrinol 159: 1-5 [Abstract] [Full Text]  
• Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al-Shamma, H., Smith, B., Chalmers, D., Behan, D. (2008). Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization. J. Pharmacol. Exp. Ther. 325: 577-587 [Abstract] [Full Text]  
• Londahl, M., Nilsson, A., Lindgren, H., Katzman, P. (2008). A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.. Eur J Endocrinol 158: 583-585 [Abstract] [Full Text]  
• Miller, K. J., Azzara, A. V. (2008). An Old Dog Learns a New Trick: Regulation of Peripheral Glucose Homeostasis by the Serotonin (5-HT)2C Receptor. Mol. Interv. 8: 73-77 [Abstract] [Full Text]  
• Gornemann, T., Hubner, H., Gmeiner, P., Horowski, R., Latte, K. P., Flieger, M., Pertz, H. H. (2008). Characterization of the Molecular Fragment That Is Responsible for Agonism of Pergolide at Serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A Receptors. J. Pharmacol. Exp. Ther. 324: 1136-1145 [Abstract] [Full Text]  
• Melmed, S. (2008). Update in Pituitary Disease. J. Clin. Endocrinol. Metab. 93: 331-338 [Abstract] [Full Text]  
• Zolkowska, D., Baumann, M. H., Rothman, R. B. (2008). Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels. J. Pharmacol. Exp. Ther. 324: 791-797 [Abstract] [Full Text]  
• Corvol, J.-C., Anzouan-Kacou, J.-B., Fauveau, E., Bonnet, A.-M., Lebrun-Vignes, B., Girault, C., Agid, Y., Lechat, P., Isnard, R., Lacomblez, L. (2007). Heart Valve Regurgitation, Pergolide Use, and Parkinson Disease: An Observational Study and Meta-analysis. Arch Neurol 64: 1721-1726 [Abstract] [Full Text]  
• Lindsay, A. (2007). JournalScan. Heart 93: 645-647 [Full Text]  
• Stephens, J. W., Price, D. E., Ionescu, A., Linkova, H., Ruzicka, E., Penicka, M., Kast, R. E., Altschuler, E. L., Ziegler, J. L., Bukhman, G. Y., Sartiani, L., Cerbai, E., Mugelli, A., Schade, R., Andersohn, F., Garbe, E., Zanettini, R., Pezzoli, G., Roth, B. L. (2007). Dopamine Agonists and Valvular Heart Disease. NEJM 356: 1676-1680 [Full Text]  
• (2007). Dopamine Agonists and Heart Valve Changes. JWatch Neurology 2007: 2-2 [Full Text]  
• (2007). Dopamine Agonists and Cardiac Valvular Disease. JWatch General 2007: 3-3 [Full Text]  
• (2007). Dopamine Agonists and the Risk for Valvular Heart Disease. Journal Watch Cardiology 2007: 2-2 [Full Text]